期刊文献+

帕米膦酸二钠对长期服用糖皮质激素的特发性血小板减少性紫癜患者骨密度的影响 被引量:1

下载PDF
导出
摘要 目的探讨帕米膦酸二钠联合碳酸钙维生素D对特发性血小板减少性紫癜(ITP)患者长期应用糖皮质激素(GCS)所造成的骨量丢失的有效性和安全性。方法 116例ITP患者随机分为观察组和对照组各58例,均每日2次给予碳酸钙维生素D 300 mg治疗,观察组同时加用帕米膦酸二钠60 mg,每月1次。结果治疗6个月后,2组血钙、血磷含量与治疗前比较差异均无统计学意义(P>0.05);碱性磷酸酶及全段甲状旁腺激素含量均低于治疗前,且观察组明显低于对照组(P<0.05);腰椎和股骨颈骨密度检测2组均较治疗前上升,且观察组明显高于对照组(P<0.05)。结论 ITP患者联合帕米膦酸二钠能有效改善GCS长期应用所造成的骨量丢失,增加骨密度,最大限度地预防骨质疏松的发生。
出处 《疑难病杂志》 CAS 2010年第8期611-612,共2页 Chinese Journal of Difficult and Complicated Cases
  • 相关文献

参考文献6

二级参考文献19

  • 1万学峰,牛文光,惠艳.糖皮质激素性骨质疏松的治疗进展[J].临床荟萃,2004,19(18):1075-1077. 被引量:9
  • 2张俊,葛宁,黄晓丽,张新军.骨质疏松症的药物治疗评价[J].中国实用内科杂志:临床前沿版,2006,26(2):313-315. 被引量:25
  • 3王义生,胡新永.糖皮质激素性骨质疏松症的防治研究进展[J].河南医学研究,2006,15(2):185-188. 被引量:9
  • 4糖皮质激素性骨质疏松症诊疗指南(讨论稿)[J].中华全科医师杂志,2006,5(8):460-461. 被引量:27
  • 5Hirayama T, Sabokbar A, Athanasou NA. Effect of corticosteroids on human osteoclast formation and activity[ J]. J Endocrinol, 2002,175( 1 ) : 155 - 163.
  • 6Durieux S, Mercadal L, Oreel P, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients[J] .Transplantation, 2002,74(4) :496 - 500.
  • 7Yood RA, Harrold LR, Fish L, et al. Prevention of glucocorticoid induced osteoporosis [ J]. Arch Intern Med, 2001,161(5) : 1322 - 1327.
  • 8Homik J, Suarez-Mmazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid induced osteoporosis[ J]. Cochrane Database Syst Rev, 2000,10(2) :952 - 957.
  • 9Krieg MA, Seydoux C, Sandini L, et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study [J]. Osteoporosis Int, 2001, 12(2):112- 116.
  • 10Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of supplementation with calcium and cholecalciferol (vitamin D3 ) for prevention of fractures in primary care[J]. BMJ, 2005,330(5) :1003 - 1006.

共引文献1691

同被引文献59

  • 1Buttgereit FR, Iipworth BJ. Optimised glucocorticoid therapy:the sharpe- ning of an old spear[ J~. Lancet,2005,365 (9461) :801-803.
  • 2Den Uyl DE, Lems WF. Advances in glucocorticoid-induced osteoporosis[J]. Curr Rheumatol Rep ,2011,13 (3) :233-240.
  • 3Stewart PM, Krozowski ZS. 11 beta-hydroxysteroid dehydrogenase [ J 1. Vitam Horm, 1999, 57:249-324.
  • 4Mckay LI, Cidlowski JA.Cross-talk between nuclear factor-kappa B and the steroid hormone receptors : mechanisms of mutual antagonism [ J ]. Mol Endocrinol, 1998,12 ( 1 ) :45-56.
  • 5Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiin- flammatory activity in vivo[ J ]. Mol Endocrinol, 1997, 11 (9) :1245- 1255.
  • 6Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treat- ment of rheumatic diseases: an update on the mechanisms of action [ J ]. Arthritis Rheum ,2004,50 ( 11 ) :3408-3417.
  • 7Aulakh R, Singh S. Strategies for minimizing corticosteroid toxicity: a review [ J 1. Indian J Pediatr,2008,75 (10) : 1067-1073.
  • 8Curtis JR,Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucoeorticoid use [ J ]. Arthritis Rheum ,2006,55 ( 3 ) :420-426.
  • 9Cushing, H. The basophil adenomas of the pituitary body and their clini- cal manifestations ( pituitary basophilism) [ J ]. Obes Res, 1994,2 ( 5 ) : 486-508.
  • 10Kanis JA, Stevenson M, Mecloskey EV, et al. Glucocortieoid-indueed os- teoporosis: a systematic review and cost-utility analysis [ J ]. Health Technol Assess,2007,11 (7) : 1-231.

引证文献1

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部